Last updated on May 2019

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

---

Brief description of study

Post-marketing safety data on patients treated and untreated with eculizumab.

Detailed Study Description

The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.